The studies make clear that achieving costs below $7 per kg will require higher-density cell cultures, more efficient use of food-grade media, food-grade equipment in facilities, significant but attainable cost reductions in recombinant protein and growth factor production, and more relaxed payback time criteria for capital expenditures, says the Good Food Institute (GFI), which commissioned the studies along with Belgian animal rights advocacy group GAIA.
The two studies - atechno-economic assessment (TEA)and a life cycle assessment (LCA)- model the costs and environmental impacts of a hypothetical commercial-scale cell-cultured meat facility churning out 10,000 metric tons of ground meat a year at a temperature of around 37C (98.6F) in 2030.
The meat in question would be a slurry or paste made out of meat cells, comparable to very finely ground meat, suitable for further formulation into meat-consumer products as opposed to a next-generation more structured, steak-like product, explain the authors at CE Delft, noting that cells from water-based species can be grown at lower temperatures (15-30C), saving some heating costs.
Basic thermodynamics dictate that growing meat from cells in bioreactors instead of living, breathing, animals should be more efficient, as resources are spent on growing only the cells that make up the meat product rather than maintaining the day-to-day activities of an entire animals body, noted GFI senior scientist Elliot Swartz, in an analysis of the studies you can read HERE.
However, there are many known unknowns (and likely some unknown unknowns too) when it comes to producing cell-cultured meat on an industrial scale, added Swartz, noting for example, to our knowledge, the large-volume perfusion bioreactor systems as described in the LCA and TEA do not yet exist.
Future work should therefore be focused on optimizing existing systems or developing new systems that can efficiently expand or differentiate skeletal muscle and adipose tissue or support co-cultures of multiple cell types, he said.
Conceptually, this could require embedding scaffolding structures within a bioreactor or using permeable biomaterials to house encapsulated cells in spheres, sheets, or tubes. Further development of fit-for-purpose perfusion bioreactors for cultivated meat production offers a large whitespace opportunity for new companies.
CE Delft looked at capital costs, maintenance, cleaning, labor, wastewater treatment; heat, electricity, culture medium costs and other inputs such as chemicals, filters, scaffolds, vials and ultrapure water; coupled with cell bank maintenance, small-scale proliferation, large-scale proliferation, differentiation and maturation, and harvesting and food safety measures.
The authors acknowledge that every firm uses a different cell culture medium, a combination of water, amino acids, sugars, salts, vitamins, recombinant proteins and growth factors signaling proteins that encourage cells to proliferate and differentiate, which come with a hefty price tag. For the purposes of this study, it selects albumin, insulin, and transferrin and FGF-2 and TGF-.
Reducing the costs of growth factors [such as FGF-2]has a substantial impact on cultivated meat costs, and limiting the use of recombinant proteins [such as albumin] together with reducing the production price seems even more vital to bring cultivated meat production costs down.
But they added: Prices are falling rapidly already, which is promising for the future.
Maximizing cell density during the proliferation stages will also be key to reducing costs, said CE Delft, which estimates that by 2030, a hypothetical cell-cultured meat facility might be able to compete with some conventional meats on cost, with production costs (as opposed to wholesale or retail prices) as low as $5.66/kg or $2.57 per pound, with hybrid meats combining plant-based and cell-cultured meats providing a near-term opportunity to further reduce costs and improve texture.
The studies did not, however, factor in specialized and automated cultivators for meat production, cell culture media recycling, or improved methods for growth factor production, which could make a significant difference to the economic equation, noted Swartz at the GFI.
The findings should not be taken as unchanging truths or as the absolute lower bounds of costs and environmental impacts of cultivated meat.
For example, he said, perhaps recombinant proteins or growth factors can be produced in less resource-intensive hosts, or manufacturers could work out how to do more with less by engineering more potent or thermostable variants, developing encapsulated or slow-release systems, using conditioned medium from other animal cell lines, relying on high-density cell cultures to become self-sustaining, or by discovering biofunctional equivalents in plants or other organisms.
Serum- and albumin-free medium formulations are commonplace for the culturing of pluripotent stem cells, which increases confidence that albumin may be able to be eliminated entirely from use in cultivated meat manufacturing.
So what about sustainability?
The environmental impact of cell-cultured meat is largely driven by energy use; primarily electricity use during production itself, but also electricity and heat use in upstream production of medium, according to CE Delfts LCA report: We therefore see that electricity use is the most important driver for the environmental single score impact of cultivated meat in a conventional energy scenario.
If renewable energy is used to power cell-cultured meat production, this could reduce global warming impacts by 17%, 52%, and 85-92%; and land use by 63%, 72%, and up to 95% vs conventional chicken, pork, and beef production, respectively, even when compared to an extremely optimistic scenario projecting reduced environmental impacts of conventional animal agriculture, including renewable energy at farm and feed operations, said Swartz at the GFI.
These conclusions are expected to be highly robust, as the study also accounts for uncertainty in cultivated meat production by conservatively assuming high energy use at the facility, which is representative of an upper estimate.
If land currently used for conventional meat production (mostly for feed) iscarefullyrepurposed to rebuild ecosystems and sequester carbon or simply grow more human-edible food, added Swartz, we can significantly offset carbon emissions, and address global food security challenges.
Consistent withprevious studies, said Swartz, cultivated meat is also expected to be less polluting than all forms of conventional meat and use significantly less blue water (found in surface and groundwater reservoirs) than conventional beef production (but about the same as chicken and pork).
It could also bring other positive benefits, including mitigation of antibiotic resistance, foodborne illness, and zoonotic disease risk associated with conventional animal agriculture, restoration of terrestrial and marine habitats, and a decreased rate of biodiversity loss.
The overall environmental score for cell-cultured meat, however, is still higher than plant-based meat, according to CE Delft.
*The 16 companies were: Cultivated meat research institute (Avian), Aleph Farms (cell cultured beef), Avant Meats (cell cultured fish), Mosa Meat (cell cultured beef), Shiok Meats (cell cultured crustaceans), SuperMeat (cell cultured poultry), Wild Type (cell cultured fish), Akron Biotech (recombinant proteins, scaffolds, cell banking systems), Black & Veatch (consulting engineering and design-build services), Buhler (extrusion and feed pre-mix), Cell-trainer Biotech (consulting engineering), Evides (water production and treatment), Merck (cell culture media and other process related products), OSPIN (bioreactors and tissue chambers for cell expansion and differentiation), Richcore (recombinant proteins), and Warner Advisors (consulting engineering).
See the original post here:
When will cell-cultured meat reach price parity with conventional meat? - FoodNavigator-USA.com
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments